C-reactive protein changes with antihypertensive and statin treatment;Variaciones de la proteína C reactiva inducidas por el tratamiento antihipertensivo e hipolipemiante

Medicina Clinica

Volumn 125, Issue 15, 2005, Pages 561-564

  Rodilla, Enríque ^a   Gómez Belda, Ana ^a   Costa, José A ^a   Aragó, Miriam ^a   Miralles, Amparo ^a   González, Carmen ^a   Pascual, José M ^a  

^a HOSPITAL DE SAGUNTO   (Spain)

Author keywords

Antihypertensive treatment; Coronary risk; hs CRP; Statin treatment

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; C REACTIVE PROTEIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY RISK; DIASTOLIC BLOOD PRESSURE; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NEPHELOMETRY; PROTEIN BLOOD LEVEL; RANK SUM TEST; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SYSTOLIC BLOOD PRESSURE;

EID: 28444445635     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13080650     Document Type: Article

References (30)

1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-26.
2. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary Heart disease: meta-analyses of prospective studies. JAMA. 1998;279:1477-82.
3. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-9.
4. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101:1767-72.
5. Rohde LE, Hennekens CH, Ridker PM. Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men. Am J Cardiol. 1999; 84:1018-22.
6. Albert MA, Danielson E, Rifai N, Ridker PM; PRINCE Investigators. The Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286:64-70.
7. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al and Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344:1959-65.
8. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation. 1999;100:230-5.
9. Ridker PM. Should statin therapy be considered for patients with elevated C-reactive protein? The need for a definitive clinical trial. Eur Heart J. 2001;22:2135-7.
10. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
11. Chobanian A, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High blood Pressure. The JNC 7 report. JAMA. 2003;289:2560-72.
12. Petrie JC, O'Brien ET, Littler WA, De Swiet M; British Hypertension Society. Recommendations on blood pressure measurement. Br Med J. 1986;293:611-5.
13. Friedewald WT, Levy RJ, Frederickson DS. Estimation of the concentration of low-density lipoproteins cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem. 1972;18: 499-502.
14. Whicher JT, Ritchie RF, Johnson AM, Baudner S, Bienvenu J, Blirup-Jensen S, et al. New international reference preparation for proteins in human serum (RPPPHS). Clin Chem. 1994;40:934-8.
15. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO III, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511.
16. Ridker PM, Rifai N, Pfeffer M, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation. 1999;100:230-5.
17. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286:64-70.
18. Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation. 2001;103:1191-3.
19. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 1998;98:839-44.
20. Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation. 2001;103:1191-3.
21. Ethan M, Balk EM, Lau J, Goudas LC, Jordan HS, Kupelnick B, et al. Effects of statins on non-lipid serum markers associated with cardiovascular disease. A systematic review. Ann Intern Med. 2003;139:670-82.
22. Van de Ree MA, Huisman MV, Princen HMG, Meinders AE, Kluft C, the DALI-Study Group. Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis. 2003;166:129-35.
23. Bautista LE, López-Jaramillo P, Vera LM, Casas JP, Otero AP, Guaracao AI. Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens. 2001;19:857-61.
24. Sung KC, Suh JY, Kim BS, Kang JH, Kim H, Lee MH, et al. High sensitivity c-reactive protein as an independent risk factor for essential hypertension. Am J Hypertens. 2003;16:429-33.
25. Ford ES. C-reactive protein concentration and cardiovascular disease risk factors in children: findings from the National Health and Nutrition Examination Survey 1999-2000. Circulation. 2003;108:1053-8.
26. Bautista LE, Vera LM, Arenas IA, Gamarra G. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J Hum Hypertens. 2005;19:149-54.
27. Stuveling EM, Bakker SJL, Hillege HL, Burgerhof JHG, De Jong PE, Gans ROB, et al, for the PREVEND Study Group. C-Reactive Protein Modifies the Relationship Between Blood Pressure and Microalbuminuria. Hypertension. 2004;43:791-6.
28. Ridker PM. High-sensitivity C-reactive protein and cardiovascular risk: Rationale for screening and primary prevention. Am J Cardiol. 2003;92 Suppl:17K-22K.
29. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107:363-9.
30. Gómez-Belda A, Rodilla E, Albert A, García L, González C, Pascual JM. Uso clínico de las estatinas y objetivos terapéuticos en relación con el riesgo cardiovascular. Med Clin (Barc). 2003;121:527-31.